Multi-Cancer Early Detection 101-Multi-Cancer Early Detection 101

Video Transcription

Video Summary

The webinar introduced multi-cancer early detection (MCED) testing, which aims to identify several cancers at once through a simple blood test. Dr. Chetan Bediagauda explained the need for MCED because only a few cancers currently have effective screening, and many cancers are still found late, when survival is much worse. He reviewed key challenges, including test accuracy, avoiding false positives and overdiagnosis, cost, accessibility, and how to communicate results to patients.<br /><br />Dr. Bediagauda summarized recent research using different biomarker approaches such as DNA methylation, fragmentomics, mutations, copy number changes, and protein markers. He highlighted several studies showing promising sensitivity and specificity, including retrospective and prospective trials like DETECT-A, CCGA, and Pathfinder. These studies suggest MCED tests can detect cancers earlier, including cancers without standard screening methods, and may complement—not replace—existing screening like mammography or colonoscopy.<br /><br />In the Q&A, he emphasized that more safety data are needed before broad rollout, especially to understand false positives. He also noted MCED could help reduce disparities if it becomes affordable and easy to access, and that implementation will require multidisciplinary team support and rapid follow-up pathways. He predicted MCED could be widely integrated into routine care within about five years.

Keywords

multi-cancer early detection

MCED testing

blood test

cancer screening

biomarkers

false positives

early cancer detection